FDAnews Drug Daily Bulletin

Gilead’s PAH Candidate Scrapped After Missing Primary Endpoint in Study

Aug. 24, 2012
Gilead Sciences’ pulmonary arterial hypertension (PAH) drug cicletanine did not meet its primary endpoint in a Phase II trial, leading Gilead to terminate the study and drop plans to further develop the drug for PAH. Cicletanine, an oral, once-daily drug approved in some EU countries to treat hypertension, was not significantly better than placebo for helping patients with PAH walk farther in a six-minute walking test at 12 weeks.
Drug Industry Daily